# Utidelone

Source: https://onco.cc/drugs/utidelone/  
OnCo record `utidelone` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes.

## Summary

Utidelone is a genetically engineered epothilone analogue produced by fermentation, developed by Biostar Pharmaceuticals in Chengdu. The NMPA approved it in March 2021 in combination with capecitabine for recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane, after a phase 3 trial showed longer progression-free and overall survival than capecitabine alone. An oral form is in later trials.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Also known as: Youheng
- Tags: china; nmpa-approved
- Code: UTD1
- Modality: Epothilone analogue, microtubule-stabilising cytotoxic chemotherapy
- Mechanism: Binds tubulin and locks microtubules in place so that dividing cells cannot complete mitosis; it works in cells that have become resistant to taxanes.
- Approvals: CN 2021: Recurrent or metastatic breast cancer after anthracycline and taxane, with capecitabine

## Sources

- ClinicalTrials.gov: trials of utidelone: https://clinicaltrials.gov/search?intr=utidelone

## Connected records

- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- targets: [Tubulin (microtubules)](https://onco.cc/targets/tubulin/)
- companies: [Biostar Pharmaceuticals](https://onco.cc/companies/biostar-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/utidelone.json